Kane Biotech Announces Q2 Earnings Release and Inaugural Business Update Video
WINNIPEG, Manitoba, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that they will release second quarter fiscal 2019 earnings on Wednesday, August 21st after market close. The company is pleased to announce that they will be hosting their first-ever business update in lieu of an earnings conference call this quarter. The business update video will feature presentations from several members of Kane’s team and will go live on September 10th at 4:30pm EST.
Both the Q2 earnings release and the business update video will be available on Kane’s investor site at https://ir.kanebiotech.com/press-releases.
“We have been very successful and have seen great progress with both our Animal Health and Human Health businesses. We continue to engage with several new partners and distributors in order to grow sales, expand into new markets and grow our product portfolios. I look forward to shedding more light on these recent progressions as well as on what we have planned for the months to come,” stated Marc Edwards, Chief Executive Officer at Kane Biotech.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (56 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit www.kanebiotech.com, or contact:
Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
+1 (514) 910-6991
medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
+1 (204) 298-2200
rdupuis@kanebiotech.com
Joe Green
US. Investor Relations
Edison Inc.
+1 (646) 653-7030
jgreen@edisongroup.com
Laine Yonker
US. Investor Relations
Edison Inc.
+1 (646) 653 7035
lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
Released August 14, 2019